CD4 and neoplasm: Our results support the requirement of CD4+ T cells for tumor control in an MHCII-dependent manner, and for sustained control of GBM, which depends on a memory CD4+ T-cell subset, whose signature is also correlated with better survival in our G207 clinal trial patients and TCGA-GBM patients.